Project Grant R01AI175635
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded the University of Arizona a Project Grant of $3,075,549 under the Allergy and Infectious Diseases Research program (CFDA 93.855) on July 28, 2025, with a completion date of June 30, 2029. This research initiative investigates airway innate immune responses to Coccidioides infection, a serious fungal disease commonly known as valley fever that is expanding geographically across the United States. The research focuses on...
- Shy Therapeutics, LLC received a $300,616 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective September 1, 2025, through August 31, 2027. The award supports the development of a novel class of antifungal small-molecule therapeutics designed to address the growing public health threat of drug-resistant fungal infections. The project will deliver research products including...
- Federal Project Grant Award Summary Texas A&M University System Health Science Center received a $192,500 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on June 1, 2026, with completion scheduled for May 31, 2028. The award supports a two-year research initiative focused on developing novel antifungal therapeutics to combat multi-drug-resistant fungal infections,...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $438,038 to the Regents of the University of California, Berkeley, under the Allergy and Infectious Diseases Research program (CFDA 93.855) for a two-year project period running from July 15, 2025 through June 30, 2027. This Project Grant funds a molecular research initiative investigating the regulation of infectious spore formation in Coccidioides posadasii, the fungal pathogen...
- Federal Grant Award Summary Prokaryotics Incorporated received a $299,697 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded September 19, 2025, with a completion date of August 31, 2026. The award supports the development of a mechanistically novel antifungal agent targeting fks1 and cell wall 1-3-D-glucan biosynthesis to address life-threatening fungal infections in hospital...
- Federal Project Grant Award Summary Life Pharms Inc. received a $300,000 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 19, 2025, with completion targeted for August 31, 2027. The award supports the development of LP10581, a novel small-molecular-weight antifungal compound designed to address the critical public health challenge of drug-resistant fungal...
- This National Science Foundation (NSF) Biological Sciences Program (CFDA 47.074) project grant in the amount of $240,000 will fund a postdoctoral research fellowship from July 1, 2024 to June 30, 2027. The research will investigate the environmental drivers of soil fungal pathogen spread, focusing on Coccidioides immitis, the pathogen that causes Valley Fever. The project aims to uncover the roles of landscape structure and local climate in shaping fungal pathogen distributions using genomic...
- Federal Project Grant Award Summary Halomine Inc. (doing business as Avantguard) received a $299,435 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop and optimize a novel, bio-inspired chloramine-based antifungal treatment for cutaneous fungal infections. The award, effective August 1, 2025 through July 31, 2026, supports the advancement of a stabilized chloramine polymer...
- Project Summary The University of Michigan has received a $603,601 Project Grant award effective August 1, 2025 through July 31, 2030 from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The award funds research aimed at developing novel protease inhibitors to cure chronic Toxoplasma gondii (TG) infection, a parasitic condition that causes reactivated ocular toxoplasmosis, a leading infectious cause of...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded University of California, Davis a $441,204 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to conduct research on preventing invasive candidiasis caused by Candida albicans. The award, issued February 13, 2026, with a completion date of January 31, 2028, funds biomedical research aimed at understanding and preventing systemic fungal infections in...
NOVEL ANTIFUNGAL AGENTS AGAINST COCCIDIOIDOMYCOSIS - PROJECT SUMMARY. FUNGAL INFECTIONS CAUSED BY DIMORPHIC FUNGI COCCIDIOIDES IMMITIS AND COCCIDIOIDES POSADASII ARE ENDEMIC TO THE SOUTHWESTERN PARTS OF THE UNITED STATES AND THE SELECTED AREAS IN THE WESTERN HEMISPHERE. WHILE MOST INFECTIONS ARE MILD AND, SYMPTOMATIC PNEUMONIA CAN BE EXTREMELY DIFFICULT TO TREAT AND REQUIRES LIFELONG AZOLE THERAPY UNDERSCORING THE NEED FOR NEW THERAPEUTIC OPTIONS. IN THIS RESPECT, TARGETING THE HIGH-OSMOLARITY GLYCEROL (HOG) MITOGEN-ACTIVATED PROTEIN KINASE (MAPK) PATHWAY, AND, SPECIFICALLY, HYBRID HISTIDINE KINASES (HHKS), REPRESENTS A PROMISING APPROACH BECAUSE HHKS ARE NOT PRESENT IN HUMANS BUT ARE CRITICAL COMPONENTS OF CELLULAR RESPONSES TO OXIDATIVE STRESS IN PATHOGENIC FUNGI. WE HAVE IDENTIFIED A NATURAL PRODUCT CANDIDATE THAT SHOWS POTENT FUNGICIDAL ACTIVITY AGAINST COCCIDIOIDES IN A MURINE MODEL. THE OVERARCHING GOAL OF THIS COLLABORATIVE PROJECT IS TO OPTIMIZE ANTIFUNGAL ACTIVITY OF SYNTHETIC ANALOGS AS A POTENTIAL LEAD FOR VALLEY FEVER TREATMENT. IN AIM 1, WE WILL PERFORM RATIONAL SAR STUDY ON A LEAD CANDIDATE BY INTRODUCING MODIFICATIONS IN THREE DISTINCT PARTS OF THE MOLECULE. IN AIM 2, WE WILL STUDY THE MECHANISM OF ACTION OF THE LEAD CANDIDATES AND FINE-TUNE IN SILICO MODEL TO GUIDE RATIONAL ANALOG PREPARATION. IN AIM 3, WE WILL PERFORM PK/PD STUDIES AND VALIDATE THE ACTIVITY OF THE OPTIMIZED CANDIDATE IN A MURINE MODEL OF COCCIDIOIDOMYCOSIS. COLLECTIVELY, THIS STUDY WILL RESULT IN A SMALL MOLECULE FUNGICIDE WITH OPTIMIZED PROPERTIES FOR FUTURE PRE-CLINICAL WORK.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $748.7k | 5/12/25 | ||
| Not listed | $74.6k | 9/13/24 | ||
| Not listed | $74.6k | 9/13/24 | ||
| Not listed | $673.3k | 7/17/24 | ||
| Not listed | $673.3k | 7/17/24 |
GrantNumber | Description | Subgrantee | Prime Award | Dollars Obligated | Updated At |
|---|---|---|---|---|---|
1566448S | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Project Grant R01AI175635 | $80.2k | 3/9/26 | |
1566447S | Northern Arizona University | Project Grant R01AI175635 | $211.1k | 10/31/25 |